HighTower Advisors LLC Buys 5,725 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• HighTower Advisors increased its Regeneron stake by 9.7%, purchasing 5,725 additional shares to hold 64,650 shares valued at approximately $40.3 million. Institutional investors collectively own 83.31% of the company.
• Regeneron reported quarterly EPS of $14.29, exceeding analyst expectations of $10.16, while revenue reached $4.29 billion and increased 16.7% year over year.
• Shares opened at $827.72, near their 12-month high, while analysts maintain a “Moderate Buy” consensus with an average price target of $800.36. The company also pays a quarterly dividend of $0.94 per share, yielding about 0.5%.

HighTower Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 64,650 shares of the biopharmaceutical company's stock after purchasing an additional 5,725 shares during the quarter. HighTower Advisors LLC owned 0.06% of Regeneron Pharmaceuticals worth $40,312,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. California State Teachers Retirement System grew its stake in Regeneron Pharmaceuticals by 63,274.2% in the second quarter. California State Teachers Retirement System now owns 97,723,683 shares of the biopharmaceutical company's stock worth $60,934,625,000 after purchasing an additional 97,569,482 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $5,682,636,000. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $1,012,296,000. Price T Rowe Associates Inc. MD grew its position in shares of Regeneron Pharmaceuticals by 142.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company's stock worth $1,504,991,000 after buying an additional 1,144,887 shares in the last quarter. Finally, Nuveen LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.1% during the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company's stock valued at $1,551,858,000 after buying an additional 835,240 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $827.72 on Tuesday. The stock has a 50 day moving average of $742.21 and a 200 day moving average of $719.75. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The stock has a market cap of $85.22 billion, a P/E ratio of 20.46, a P/E/G ratio of 1.62 and a beta of 0.20. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.Regeneron Pharmaceuticals's revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the previous year, the company posted $12.81 earnings per share. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 9.29%.

Insider Activity

In other news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director directly owned 1,703 shares of the company's stock, valued at $1,362,400. This represents a 31.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the sale, the director owned 603 shares in the company, valued at $512,550. This trade represents a 39.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,146 shares of company stock worth $3,432,488 in the last ninety days. Corporate insiders own 6.97% of the company's stock.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research reports. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Royal Bank Of Canada boosted their price target on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a "sector perform" rating in a report on Friday, July 31st. JPMorgan Chase & Co. lowered their price target on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an "overweight" rating for the company in a research report on Monday, May 18th. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an "outperform" rating on the stock in a research note on Monday, May 18th. Finally, HSBC cut their price objective on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a "buy" rating on the stock in a report on Monday, July 6th. Fourteen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $800.36.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.